San Diego–based Tandem said it agreed to combine its insulin delivery systems with Abbott’s future dual glucose-ketone sensor. The companies aim to provide more options for people to manage their diabetes.
This marks the second recent collaboration announcement of this kind related to the highly anticipated Abbott sensor. Last month, Sequel Med Tech agreed to integrate its twiist automated insulin delivery system with the dual sensor.
Abbott is currently developing the sensor to combine glucose- and ketone- sensing technology. It aims to help people with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. (Abbott Diabetes SVP of Commercial Operations, Chris Scoggins, spoke to Drug Delivery Business News last year about how the dual sensor fits into the company’s future plans. Read here.)
Tandem and Abbott already have previous integrations under their belt. They announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in January 2024.
“Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes,” said John Sheridan, Tandem president and CEO. “We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future.”
